Blue Crest Capital Management LTD Alnylam Pharmaceuticals, Inc. Transaction History

Blue Crest Capital Management LTD

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 14, 2019	SELL	$62.67 - $88.33 $211,636 - $298,290	-3,377 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$87.52 - $122.67 $295,555 - $414,256	3,377 New	3,377 $296,000
Q1 2018 May 15, 2018	SELL	$115.92 - $148.54 $525,001 - $672,737	-4,529 Closed	0 $0
Q4 2017 Feb 14, 2018	SELL	$114.49 - $139.98 $1.31 Million - $1.6 Million	-11,426 Reduced 71.61%	4,529 $575,000
Q3 2017 Nov 14, 2017	BUY	$72.53 - $118.27 $1.16 Million - $1.89 Million	15,955	15,955 $1.88 Million

675

108M

839K

771K

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $28.9B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Blue Crest Capital Management LTD, based on Form 13F filings with the SEC.

Stay updated on Blue Crest Capital Management LTD with notifications on news.